{"url_path":"/sec/aurx/8-k/2026-06-03/item-9-01","section_key":"item-9-01","section_title":"Item 9.01 Financial Statements and Exhibits**","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-06-03","source_url":"https://www.sec.gov/Archives/edgar/data/1091596/0001437749-26-019199-index.html","accession_number":"0001437749-26-019199","cik":"0001091596","ticker":"AURX","issuer_name":"Nuo Therapeutics, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1091596/0001437749-26-019199-index.html","primary_entity_key":"0001091596","primary_entity_name":"Nuo Therapeutics, Inc."},"word_count":187,"has_tables":true,"body_markdown":"**Item 9.01 Financial Statements and Exhibits**\n\n \n\n(d) Exhibits\n\n \n\nExhibit No.\n \nDescription\n \n\n \n \n \n\n4.1\n\n \n\n[Form of Interim Warrants](ex_971113.htm)\n\n4.2\n\n \n\n[Form of Second Warrants (previously filed on January 26, 2026 as Exhibit 4.2 to the registrant’s Current Report on Form 8-K and incorporated by reference herein)](http://www.sec.gov/Archives/edgar/data/1091596/000143774926002078/ex_911187.htm)\n\n4.3\n\n \n\n[Form of Second Restated Warrants](ex_971172.htm)\n\n4.4\n\n \n\n[Form of Prepayment Warrants (previously filed on January 26, 2026 as Exhibit 4.3 to the registrant’s Current Report on Form 8-K and incorporated by reference herein)](http://www.sec.gov/Archives/edgar/data/1091596/000143774926002078/ex_910895.htm)\n\n4.5\n\n \n\n[Form of Prepayment Restated Warrants](ex_971173.htm)\n\n4.6\n\n \n\n[Form of Interest Warrants (previously filed on January 26, 2026 as Exhibit 4.4 to the registrant’s Current Report on Form 8-K and incorporated by reference herein)](http://www.sec.gov/Archives/edgar/data/1091596/000143774926002078/ex_910896.htm)\n\n10.1\n\n \n\n[Amended and Restated Loan and Security Agreement, dated as of May 29, 2026](ex_971174.htm)\n\n104\n\n \n\nCover Page Interactive Data File (embedded within the Inline XBRL document)\n\n \n\n \n\n \n\n**SIGNATURES**\n\n \n\nPursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.\n\n \n\n**Nuo Therapeutics, Inc.**\n\nBy:\n\n/s/ David E. Jorden\n\nDavid E. Jorden\n\nChief Executive and Chief Financial Officer\n\n \n\nDate: June 2, 2026"}